Total
0
Shares
Zelira Therapeutics (ASX:ZLD) - Managing Director, Dr Richard Hopkins
Managing Director, Dr Richard Hopkins
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zelira Therapeutics (ZLD) will form a U.S. subsidiary to commercialise its hemp-derived cannabinoid-based oral care products
  • The first over-the-counter product will be launched this year, a cannabinoid- containing toothpaste developed by Sprinjene CEO and Founder Dr Sayed Ibrahim
  • The Zelia-Sprinjene products will be manufactured by Natural Beauty USA
  • Shares are trading 3.45 per cent higher at six cents

Zelira Therapeutics (ZLD) will form a U.S. subsidiary to commercialise its hemp-derived cannabinoid-based oral care products.

The first over-the-counter product will be launched this year, a cannabinoid- containing toothpaste developed by Sprinjene CEO and Founder Dr Sayed Ibrahim.

Sprinjene produces gluten-free, cruelty-free, vegan, kosher, USDA bio-preferred, and halal oral care products, which are manufactured by Natural Beauty USA.

Sayed said the Sprinjene team is excited about the partnership with Zelira.

“Our collaboration to commercialize the most advanced hemp-derived cannabinoid-based oral care products expands our reach into new oral care markets where every person can access the daily benefit of using our products,” he noted.

The Zelia-Sprinjene products will also be manufactured by Natural Beauty.

Zelia’s CEO and Managing Director in the U.S., Dr Oludare Odumosu, said the toothpaste is just one of five products the company expects to launch this year.

“Our products will be available for sale in the U.S. by the fourth quarter of 2020 and we remain focused on unlocking the benefits of cannabinoid-based applications as we expand our company’s reach into new and lucrative markets,” Oludare explained.

“This will be the first over-the-counter product line launched by Zelira,” he added.

Shares are trading 3.45 per cent higher at six cents at 10:20 am AEST.

ZLD by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.